DE1929921A1 - New 1-alyl-1,2,5,6-tetrahydro-3-pyridylmethyl-carboxylic acid esters and their acid addition salts and quaternary ammonium compounds - Google Patents
New 1-alyl-1,2,5,6-tetrahydro-3-pyridylmethyl-carboxylic acid esters and their acid addition salts and quaternary ammonium compoundsInfo
- Publication number
- DE1929921A1 DE1929921A1 DE19691929921 DE1929921A DE1929921A1 DE 1929921 A1 DE1929921 A1 DE 1929921A1 DE 19691929921 DE19691929921 DE 19691929921 DE 1929921 A DE1929921 A DE 1929921A DE 1929921 A1 DE1929921 A1 DE 1929921A1
- Authority
- DE
- Germany
- Prior art keywords
- carbon atoms
- ammonium compounds
- addition salts
- tetrahydro
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 title claims description 34
- 150000003839 salts Chemical class 0.000 title claims description 22
- 150000003856 quaternary ammonium compounds Chemical class 0.000 title claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- -1 3-hexyl Chemical group 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 claims 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 2
- 150000003868 ammonium compounds Chemical class 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229940087675 benzilic acid Drugs 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960004738 nicotinyl alcohol Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- IUBMRJVNZLQSHU-FDJBSCRHSA-N monate-a Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(O)=O)OC1 IUBMRJVNZLQSHU-FDJBSCRHSA-N 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- NRTLTGGGUQIRRT-UHFFFAOYSA-N triethylazanium;bromide Chemical compound [Br-].CC[NH+](CC)CC NRTLTGGGUQIRRT-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Case 1/321
We/ERCase 1/321
We / ER
Dr. F Zumetein »en. - Dr. E. A·9·? Dr.lt Koenlg.berger - Dip«. Phy·· »· Holzhauer Dr. F Zumetein »en. - Dr. E. A · 9 ·? Dr.lt Koenlg.berger - Dip «. Phy ·· »· Woodcutter
Dr. F. Zumstain |un.Dr. F. Zumstain | un.
Patentanwalt«Patent attorney "
8 Mönchen 2. BräuhouMtraße 4/IU8 monks 2. BräuhouMtraße 4 / IU
. C. p. BOEHRINGER SOHIi, Ingelheim/Hh. C. p. BOEHRINGER SOHIi, Ingelheim / Hh
Neue 1-Alkyl-1,2,5, ö-tetrahydro^-pyridylmethyl-carbonsäureester sowie deren Säureadditionssalze und quaternäre AmmoniumverbindungenNew 1-alkyl-1,2,5, δ-tetrahydro ^ -pyridylmethyl-carboxylic acid esters as well as their acid addition salts and quaternary ammonium compounds
Die Erfindung betrifft neue l-Alkyl-l,2,5,6-tetrahydro~3· pyridylmethyl-carbonsäureester der allgemeinen FormelThe invention relates to new 1-alkyl-1,2,5,6-tetrahydro ~ 3 · pyridylmethyl carboxylic acid esters of the general formula
1 A1 A
CH9 -O-C-C- IUCH 9 -OCC- IU
R4 ' R 4 '
UJUJ
909881/1709909881/1709
2 -2 -
sowie deren Säureadditionssalze und quaternären Ammoniumverbindungen. as well as their acid addition salts and quaternary ammonium compounds.
In dieser Formel bedeuten;In this formula mean;
R-, einen gegebenenfalls durch eine Cyano- oder Alkoxygruppe substituierten Alkylrest mit 2-10 Kohlenstoffatomen, einen verzweigten Alkylrest mit 3-5 Kohlenstoffatomen, einen gegebenenfalls durch ein Halogenatom substituierten Alkenylrest mit 2 --3 Kohlenstoffatomen, einenR-, one optionally through a cyano or alkoxy group substituted alkyl radical with 2-10 carbon atoms, a branched alkyl radical with 3-5 carbon atoms, an alkenyl radical optionally substituted by a halogen atom and having 2-3 carbon atoms, a
* Alkinylrest mit 2-3 Kohlenstoffatomen, einen Cycloalkylrest mit 3-6 Kohlenstoffatomen oder einen Phenylalkylrest, * Alkynyl radical with 2-3 carbon atoms, a cycloalkyl radical with 3-6 carbon atoms or a phenylalkyl radical,
Rg Wasserstoff, Methyl, die Hydroxygruppe oder ein Chloratom, Rg hydrogen, methyl, the hydroxyl group or a chlorine atom,
R, Wasserstoff, den Phenyl- oder einen Cycloalkylrest mit 5-6 Kohlenstoffatomen oder R2 und R* zusammen einen 5- oder 6-gliedrigen cycloaliphatisehen Ring und R/. einen Phenylrest, wobei, wenn Rx und R, je einen Phenylring darstellen, diese Ringe gegebenenfalls in o-Stellung zur Verknüpfungsstelle mit dem OC-C-Atom der Essigsäure durch eine direkte Bindung oder über ein Sauerstoffatom miteinander verbunden sind.R, hydrogen, the phenyl or a cycloalkyl radical with 5-6 carbon atoms or R 2 and R * together form a 5- or 6-membered cycloaliphatic ring and R /. a phenyl radical, where, if R x and R each represent a phenyl ring, these rings are optionally connected to one another in the o-position to the point of attachment with the OC-C atom of acetic acid by a direct bond or via an oxygen atom.
I.I.
Die neuen Verbindungen lassen sich darstellenThe new connections can be displayed
a) durch Veresterung einer Verbindung der allgemeinen Formela) by esterification of a compound of the general formula
- X- X
Rl 909881/1709 _ 3 „ R l 909881/1709 _ 3 "
1929S211929S21
worin R-. die oben angeführte Bedeutung besitzt und X die Hydroxygruppe oder ein Halogenatom bedeutet, mit einer Verbindung der allgemeinen Formelwherein R-. has the meaning given above and X denotes the hydroxyl group or a halogen atom with a compound of the general formula
K2 \ I! K 2 \ I!
R3-G-C-Y IIIR 3 -GCY III
S4 S 4
worin Rp5 R·* und R, die oben angegebene Bedeutung besitzen undwherein Rp 5 R * and R, have the meaning given above and
Y die Hydroxy« oder eine Alkoxygruppe oder ein
Metall bedeutet bzwo einem anderen zur Veresterung
geeigneten Derivat dieser Verbindung nach an sich bekannten Verfahr en 9 wie sie beispielsweise in Houben-Weyl,
Methoden der Organischen Chemie„ Band XEE, Seite 508 ff
(1952) beschrieben sind,
b) durch Alkylierung eines Esters der allgemeinen FormelY is the hydroxy "or an alkoxy group or a metal means or o other suitable for esterifying derivative of this compound by known traversing en 9 as described for example in Houben-Weyl, Methoden der Organischen Chemie" Band XEE, page 508 ff (1952) are described
b) by alkylating an ester of the general formula
ί? A ί? A.
O - c - C — IUO - c - C - IU
LJLJ
R4 R 4
worin Rp5 IU raaä R, die -oben angegebene Bedeutung be~ sitzen, am Stickstoffatom äes Tetrahyäropyridinringee nach an sieh "bekannten Terfahren, wi@ si© beispielsweise in Houben-Weyl, Methoäen öer (^anisohen Glaemies Band XI/1where Rp 5 IU raaä R, have the meaning given above, on the nitrogen atom aes tetrahyropyridine rings according to known methods, such as, for example, in Houben-Weyl, Methoeaen (^ anisohen Glaemies Volume XI / 1
09881/170909881/1709
Seite 3 ff (1957) angeführt sind.Page 3 ff (1957) are cited.
Die so erhaltenen Endprodukte der allgemeinen Formel I können anschließend nach üblichen Methoden in ihre Säureadditionssalze oder die quaternären Ammoniumverbindungen überführt werden.The end products of the general formula I thus obtained can then be converted into their acid addition salts by customary methods or the quaternary ammonium compounds are converted.
Die Veresterung einer Verbindung der allgemeinen Formel II erfolgt bevorzugt unter Verwendung eines üblichen Veresterungsmittels, beispielsweise eines Acylhalogenids oder -anhydride oder durch Umsetzung einer Verbindung der Formel II, worin X ein Halogenatom bedeutet, mit einem Salz einer Carbonsäure der allgemeinen Formel III; als besonders geeignet hat sich ferner die Umsetzung eines Säureesters der Formel III (Y = O-Alkyl) mit einem Carbinol der Formel II (X = OH) erwiesen. The esterification of a compound of the general formula II is preferably carried out using a customary esterifying agent, for example an acyl halide or anhydride or by reacting a compound of the formula II, in which X is a halogen atom, with a salt of a carboxylic acid of the general formula III; The reaction of an acid ester of the formula III (Y = O-alkyl) with a carbinol of the formula II (X = OH) has also proven particularly suitable.
Die beim Verfahren a) als Ausgangsstoffe verwendeten Verbindungen der allgemeinen Formel II sind ebenfalle neu; sie können beispielsweise hergestellt werden durch Alkylierung eines Z^jSie-Tetrahydropyridln-^-carboneäüreaikylesters am Stickstoffatom und anschließender Reduktion de* Esters bei-* spielsweise· mit iifiaiumaluminlumhydrid oder durch Reduktion eines quarbären Pyridylcarbinols der FormelThe compounds of general formula II used as starting materials in process a) are also new; she can be prepared, for example, by alkylating a Z ^ jSie-Tetrahydropyridln - ^ - carboneäüreaikylesters am Nitrogen atom and subsequent reduction of the * ester at- * for example with iifiaiumaluminum hydride or by reduction of a quarinary pyridylcarbinol of the formula
^^^^ "* ^^^^ "* w 0Hw 0H
I+ I Hal "I + I Hal "
RnMarg
98 8 1/1*öSr"-^"ife'^-ii-98 8 1/1 * öSr "- ^" ife '^ - ii-
worin it-, die oben angeführte Bedeutung besitzt, mittels Natriumborhydrid„wherein it-, has the meaning given above, by means of Sodium borohydride "
Die Alkylierung einer Verbindung der allgemeinen Formel IV kann nach allen üblichen "ethcden der Substitution eines Wasserstoff atoms, das mit einem .Stickstoffatom verbunden ist 5 in an sich bekannter Weise durchgeführt werder>„The alkylation of a compound of general formula IV may, after all conventional "ethcden atom of the substitution of a hydrogen, which is connected to a .Stickstoffatom 5 carried out in a manner known per se werderfreak>"
3g kann man beispielsweise eine Verbindung der Formel I? mit einem Alky!halogenid in üblicher V/eise in die am Stickstoffatom substituierte Verbindung überführen,, Ebenso gelangt man zu den neuen Verbindungen durch Lmsetsung eines sekundären Amins der allgemeinen Formel IV mit einem Aide= hyü in Gegenwart von Ameisensäure„3g you can, for example, a compound of formula I? with an alkyl halide in the usual manner into the one on the nitrogen atom Transfer substituted compound ,, Likewise arrived one to the new connections by solving a secondary amine of the general formula IV with an Aide = hyü in the presence of formic acid "
Auch bei den nach Verfahren b) als Ausgangstoffe eiagesetzen 1S29 596°Setrahydro='3c-pyridylmethylcarbonsä'areestern der allgemeinen Formel IV handelt es sich um neue Verbindungen; sie können beispielsweise erhalten werden durch Um-= esterung dos lp29596~Ietrahydro«3-pyridylmethylalkohols mit einem Ester, vorzugsweise dem Methylester8 der gewünschten Säure der allgemeinen Formel III (Y = OH)»The 1 S 2 9 5 9 6 ° Setrahydro = '3 c -pyridylmethylcarboxylic acid esters of the general formula IV are also new compounds; they can be obtained, for example, by transesterification dos l p 2 9 5 9 6 ~ Ietrahydro "3-pyridylmethyl alcohol with an ester, preferably the methyl ester 8 of the desired acid of the general formula III (Y = OH)"
Gewünschtenfalls können die Endprodukte der allgemeinen Formel I in ihre Säureadditionssalze oder quaternären Ammo niumverbindungen überführt werden. Für diese umsetzung kom men solche Säuren infrage, die physiologisch unbedenkliche Salze liefern, beispielsweise Halogenwasserstoffsäuren, If desired, the end products of the general formula I can be converted into their acid addition salts or quaternary ammonium compounds . Acids that provide physiologically harmless salts, such as hydrohalic acids, can be used for this conversion.
- 6 -399931/1709- 6 -399931/1709
Schwefelsäure, Phosphorsäure, Salpetersäure, Oxalsäure, Zitronensäure, V/einsäure, Puraarsäure, Haieinsäure, Essigsäure, Propionsäure, Buttersäure, Methansulfonsäure, Bern steinsäureSulfuric acid, phosphoric acid, nitric acid, oxalic acid, Citric acid, V / monic acid, puraaric acid, sharkic acid, acetic acid, Propionic acid, butyric acid, methanesulfonic acid, Bern stinic acid
Die Herstellung der quaternären Ammoniumverbiuclangeu kann erfolgen durch die Umsetzung einer Verbindung der For::,.;-! "... mit allen zur Quaternierung geeigneten Verbindun^en, beispielsweise nit'Alkyl- oder Aralkylhalogenid<ü octr cn!.; einem Dialkylsulfat»The quaternary ammonium compounds can be prepared by reacting a compound of the form ::,.; -! "... with all compounds suitable for quaternization, for example nit'alkyl or aralkyl halide <ü octr cn !.; a dialkyl sulfate»
liach den oben geschilderten Verfahren können zo 3O u.ie folgenden Verbindungen., vorzugsweise in i?orra ihrer Jäure« additioHSBSilze oder qua ternär en Amcioniuicsalze, hergestellt Werdensliach the method described above may include, o 3 O u.ie following compounds., preferably in i? becoming traktorra their Jäure "additioHSBSilze or qua ternary en Amcioniuicsalze prepared
1-Äthyl-1 j 2, 5, ö-tetrahydro-S-pyridyliaethjl-bensilsäureester,
1-n-Propyl-1,2,5»6~tetrahydro-3epyridylmethyl-benzilsäureeeter,
1-Isopropyl«·!, 2,5,6-tetrahydro->3-pyridylmettiylbenzilsäureester,
l-n-Butyl-l,2,5»6~tetrahydro-3-pyridylmethyl-benzilsäureester,
l-n-Amyl
pyridylmethyl-benzilsäureester, l-1-ethyl-1 j 2, 5, ö-tetrahydro-S-pyridyliaethjl-bensilsäureester, 1-n-propyl-1,2,5 '6 ~ tetrahydro-3-pyridylmethyl e benzilsäureeeter, 1-isopropyl "· !, 2 , 5,6-tetrahydro-> 3-pyridylmettiylbenzilic acid ester, in-butyl-1,2,5-6-tetrahydro-3-pyridylmethylbenzilic acid ester, in-amyl
pyridylmethyl-benzilic acid ester, l-
dro-3-pyridylraethyl«benzilsäureester, 1-n-Hexyl-l,2,5,6-tetrahydro-3-pyriäylmethyl-benzilsäureester, 1-n-Heptyll,2,5i6-tetrahydro-3-pyridylmethyl-benzilsäurees1;er, 1-n-Octyl-1,2,5,e-tetrahydro^-pyridylmethyl-benzilsäureester, 1-n-Nonyl-l,2,5 1 e-tetrahyaro.^-pyridylmethyl-benzilsaureester, 1-n-De oyl-l,2,5,6-tβtrahydro-3-pyridylmethyl-benzii- dro-3-pyridylraethyl-benzilic acid ester, 1-n-hexyl-1,2,5,6-tetrahydro-3-pyriaylmethyl-benzilic acid ester, 1-n-heptyl, 2,56-tetrahydro-3-pyridylmethyl-benzilic acid1; he, 1-n- octyl-1,2,5, e-tetrahydro ^ -pyridylmethyl-benzilic acid ester, 1-n-nonyl-1,2,5 1 e-tetrahyaro. ^ - pyridylmethyl-benzilic acid ester, 1-n-deoyl- 1,2,5,6-tβtrahydro-3-pyridylmethyl-benzii-
- 7 -909181/1709- 7 -909181/1709
/-V: SADOBJGINAL*/ -V: SADOBJGINAL *
säureester, l-ß-(Cyanoäthyl)-1,2,5,6-tetrahydro-3-pyridylmethyl-benzilsäureester, l-ß-(Methoxyäthyl)-1,2,5,6-tetrahydro-3-pyridylmethyl-benzilsäureester, 1-Cyclopropyl-1,2,5,6-tetrahydro~3-pyridylmethyl-benzilsäureester,1-Allyl-1,2,5,6-tetrahydro-3-pyridylmethyl-benzilsäureester', l-(3-Chlor-allyl)-1,2,5,6-tetrahydro-3-pyridylmethyl-benzilsäureester, 1-Propargyl-l,2,5,6-tetrahydro-3-pyridylmethyl-benzilsäureester, 1-Phenyläthyl-1,2,5,6-tetrahydro-3-pyridylmethyl-ben zi—lsäureester, 1-Äthyl-1,2,5,6-tetrahydro-3-pyridy!methyl- « -cyclopentyl- cc -phenylessigsäureester, 1-Äthyl-l,2,5,6-tetrahydro-3-pyridylmethylot -cyclohexyl- et -phenylessigsäureester, 1-Äthyl-l ,2,5,6-tetrahydro-3-pyridylmethyl-l'-phenyl-cyclopentan-carbonsäureester, 1-Äthyl-l,2,5,6-tetrahydro-3~pyridylmethylhexahydro-bQEilsäureester. acid ester, l-ß- (cyanoethyl) -1,2,5,6-tetrahydro-3-pyridylmethyl-benzilic acid ester, l-ß- (methoxyethyl) -1, 2, 5,6-tetrahydro-3-pyridylmethyl-benzilic acid ester, 1-Cyclopropyl-1,2,5,6-tetrahydro ~ 3-pyridylmethyl-benzilic acid ester, 1-allyl-1,2,5,6-tetrahydro-3-pyridylmethyl-benzilic acid ester ', 1- (3-chloro-allyl) -1,2,5,6-tetrahydro-3-pyridylmethyl-benzilic acid ester, 1-propargyl-l, 2,5,6-tetrahydro-3-pyridylmethyl-benzilic acid ester, 1-phenylethyl-1,2,5,6-tetrahydro -3-pyridylmethyl-benzi-acid ester, 1-ethyl-1,2,5,6-tetrahydro-3-pyridy! Methyl- «-cyclopentyl- cc -phenylacetic acid ester, 1-ethyl-1,2,5,6- tetrahydro-3-pyridylmethyl-cyclohexyl-et-phenylacetic acid ester, 1-ethyl-1,2,5,6-tetrahydro-3-pyridylmethyl-1'-phenyl-cyclopentane-carboxylic acid ester, 1-ethyl-1,2,5,6 -tetrahydro-3-pyridylmethylhexahydro-bQEilic acid ester.
Die neuen Verbindungen der allgemeinen Formel I sowie ihrer Säureadditionssalze und quaternären Ammoniumverbindungen weisen starke pharmakologische, insbesondere spasmolytische und zentral'sedierende Eigenschaften auf. Sie besitzen nicht nur die gleiche Wirkungsstärke wie das bekannte Spasmolytikum AfROPIN, sondern verkörpern einen neuen Typ des Spasmolytikums, da die für solche Substanzen bisher als unabdingbar angesehenen Begleiterscheinungen wie Mydriasis, Tachycardie und, teilweise auch Sekre-r tionshemmung.praktisch gänzlich fehlen. Hervorzuheben ist insbesondere die" außerordentlich. günstige RelaMon, zwischen der erwünschten spasmolytischen Wirkung der der unerwünsch-The new compounds of general formula I and their acid addition salts and quaternary ammonium compounds have strong pharmacological, especially spasmolytic and central sedating properties. Not only do they have the same potency as that known antispasmodic AfROPIN, but embody a new type of antispasmodic, as the side effects that have hitherto been regarded as indispensable for such substances, such as mydriasis, tachycardia and, in some cases, secretion inhibition. practically completely absent. Particularly noteworthy is the "extraordinarily cheap RelaMon, between the desired spasmolytic effect of the undesirable
90988 1/1.7Q9. ,'. ......90988 1 / 1.7Q9. , '. ......
ten mydriatischen Nebenwirkung.ten mydriatic side effect.
Lacrimation und Salivation blieben im Tierversuch in den angewandten Dosen ebenfalls unbeeinflußt. Da auch keine Tachycardia beobachtet wurde, und bei einigen der neuen Verbindungen auch die aagensaftsekretionshemmende Wirkung des ÄTROPINS praktisch vollständig fehlt, sind, bei den erfindungsgemäSen Verbindungen alle unerwünschten Nebenwirkungen des ATROPINS nahezu ausgeschaltet.Lacrimation and salivation remained in the animal experiments applied doses also unaffected. Neither there Tachycardia was observed, and with some of the new compounds also the secretion-inhibiting effect des ÄTROPINE is practically completely absent, are, in the case of the invention Connections almost eliminated all undesirable side effects of ATROPIN.
Als besonders wirksam haben sich diejenigen Verbindungen der allgemeinen Formel I erwiesen, worin R^ eine Alkylgruppe mit 2 » 6 Kohlenstoffatomen.oder die Allylgruppe, R« die Hydroxygruppe und FU und R^ Phenylrsste bedeuten.Those compounds of the general formula I have proven to be particularly effective in which R ^ is an alkyl group with 2 »6 carbon atoms. or the allyl group, R «denotes the hydroxyl group and FU and R ^ denote phenyl groups.
Als Dosis für die Anwendung der neuen Verbindungen der allgemeinen Formel X werden 0,1 bis 50, vorzugsweise 1 bis-5 mg/Dosis vorgeschlagen.As a dose for the application of the new compounds of the general formula X are 0.1 to 50, preferably 1 to -5 mg / dose suggested.
Die erfindungsgemäßen Verbindungen können allein oder in Kombination mit anderen erfindungsgemäßen Wirkstoffen, gegebenenfalls auch in Kombination mit weiteren Phan»- zeutika, wie Hypnotika oder Tranquilizern zur Anwendung gelangen. Sie lassen sich in allen pharmazeutischen Zubereitungsformen anwenden und können beispielsweise in Pillen, Tabletten, Dragees, Salben, Suppositories» Lö-The compounds according to the invention can be used alone or in Combination with other active ingredients according to the invention, possibly also in combination with other Phan »- Medicines such as hypnotics or tranquilizers are used. They can be used in all pharmaceutical preparation forms and can, for example, in Pills, tablets, coated tablets, ointments, suppositories »Lö-
■,■■.■■■■."■ . '■■■ - 9 -■, ■■. ■■■■. "■. '■■■ - 9 -
90 98 81 /170990 98 81/1709
8AD QRiGWAL8AD QRiGWAL
sungen und Injektionslösungen eingearbeitet werden«solutions and injection solutions are incorporated «
Die folgenden Beispiele dienen zur näher.en Erläuterung der Erfindung?The following examples serve to provide a more detailed explanation the invention?
Beispl_el_lBeispl_el_l
6-=tetrahydro-=3-pyridylmethyl-=benzil-6- = tetrahydro- = 3-pyridylmethyl- = benzil-
g_g-ure.eg_t_er (nach Verfahren a) _ g_g-ure.eg_t_er (according to method a) _
19>7 g (O5IO MoI) 1-n-Hexyl-1,2,5,6-tetrabydro--5-pyridylcarbinol und 26,6 g (0,11 Mol) Benzilsäuremethylester wer·= den nacheinander bei 80 C in 100 ml absolutem n-Heptan gelöst» wach Zugabe von 1 nl Ka-Iiethylatlösung (4?β g Na in 100 ml Methanol) wird das Gemisch 2 Stunden unter Rück-= flufi erhitzt und das abgespaltene Methanol in einen Wasserabscheider aufgefangen., Nach Beendigung der Umesterung wird die etwa 800O warms Lösung über Aktivkohle filtriert und im Wass erstrahl vakuum eingeengt <, Ausbeute an Bass 37 g 73 % dc Thο (au® Isopropyläthsr) ° rom. Fp0= 57 - 580Oo Hydrobroraid (aus Alkohol)! Fp, ~ 135 O0 Methansulfonst (aus Alkohol)? Pp. = 141 - 14??0C BroEM&thjlmti Fp3 205 - 2060Go19> 7 g (IO O 5 MoI) 1-n-hexyl-1,2,5,6-tetrabydro - 5-pyridylcarbinol and 26.6 g (0.11 mol) Benzilsäuremethylester who · = the sequentially at 80 C Dissolved in 100 ml of absolute n-heptane, after adding 1 nl of calcium diethylate solution (4 μg of Na in 100 ml of methanol), the mixture is refluxed for 2 hours and the methanol which has been separated off is collected in a water separator completion of the transesterification is filtered about 80 0 O warms solution over active carbon and in Wass erstrahl vacuum concentrated <, yield of Bass 37 g 73% dc Th ο (au® Isopropyläthsr) ° rom mp 0 = 57 -. 58 0 Oo Hydrobroraid ( from alcohol)! Mp, ~ 135 O 0 Methanesulfonst (from alcohol)? Pp. = 141 - 14 ?? 0 C BroEM & thjlmti Fp 3 205 - 206 0 Go
wird ivie folgt erhalten:is obtained as follows:
- 10 -- 10 -
9098 81/17099098 81/1709
MoMon
a) 22,5 g (0,1 KoI) 1-n-Hexyl-i,2., 5,6-tetrahydronicotinsäuremethylester vorn Kp 0,01 - 90 - 95°C- werden innerhalb einer Stunde unter Rühren zu einer Lösung· von 2,1 g (O5055 Mol) LiAIu4 in 200 ml absolutem Äther getropfte Nach zweistündigem Erhitzen unter Rückfluß •wird abgekühlt, mit 10 mi V/asser vorsichtig zersetzt und eine i^eitere Stunde turbinierto Die AtherlösuKR ν-Ί^α filtriert j der Rückstand mehrmals mit -kleinen Ätlierpor tionen nachgewseehen und das- FiI"Grat zum Schluß isL Vakuum bei, aai., 40uG eingeengte Der aarupöse Ruckstand wird im HoGhvaktimß destilliert a Kaa erLält Ce.c 1-ii-Hesyl-l, 2, 5»6" üetrah^ciro'»3-py:;.idylt-earl)isiol a2 & ■■^r^.lcr.ss öl ^oia 7--j:.. c ^ 115 =--■ 120°ί?β in einer Äusüaute •ψοη 16 j 5 g - 84 ^ g. TIi οa) 22.5 g (0.1 KoI) 1-n-hexyl-i, 2., 5,6-tetrahydronicotinic acid methyl ester with a boiling point of 0.01 - 90 - 95 ° C- become a solution within one hour while stirring of 2.1 g (0 5 055 mol) of LiAIu 4 in 200 ml of absolute ether. After two hours of refluxing • it is cooled, carefully decomposed with 10 ml V / water and turbinated for an additional hour the residue is filtered several times with j sodas Ätlierpor functions nachgewseehen and DAS FII "burr at the end isL vacuum aai., 40 restricted u G aarupöse the residue is distilled in a HoGhvaktimß Kaa erLält Ce.c 1-ii-l-Hesyl , 2, 5 »6" üetrah ^ ciro '»3-py:;. Idylt-earl) isiol a2 & ■■ ^ r ^ .lcr.ss oil ^ oia 7 - j: .. c ^ 115 = - ■ 120 ° ί? β in one form • ψοη 16 j 5 g - 84 ^ g. TIi ο
a) 1OS s 12 g ilHol) 3°-PYrj,^'i2?«iÄ^c^rciaol ü-icl Π ρ .13 g. (1,05- Hol) n-Kexylbromid werden in 400 najletbasol gelöst und 3 Sage is <?Αΐϊ$Μ--§:<£3£ι1α&3$~ύΘΏ Gefäß auf 6C0J GL-wärmt0 In die mit 2...'· Liter Methanol ^eraüaSöe lösiiD.g werden unter Rühren.innerhalb' von-50 Minuten Bei 150C portionsweise 6294 g (I»65'Mol) XiaBH eingetrageno- Me Reaktionslösung wird 75 Minuten gerührt und anschließend, bei einer Badtemperatür von 600C im Vakuum eingeengt» Den Rückstand verteilt man zwisohen 1,5 Liter Äther und 550 ml Viasser und schüttelt die wäßrige Phase nochmals mit 500 ml Äther aus. Die vereinigten Ätherphasen werden über Kohle filtriert und nach dem Trocknen mit wasserfreiem Na2SO. unter vermin dertem Druck eingeengt. Man erhält 178,3 g = 90,3 # d. Th. a) 1OS s 12 g ilHol) 3 ° -PYrj, ^ 'i2? «iÄ ^ c ^ rciaol ü-icl Π ρ .13 g. (1.05- Hol) n-Kexylbromid are dissolved in 400 najletbasol and 3 Sage is <? Αΐϊ $ Μ - §: <£ 3 £ ι1α & 3 $ ~ ύΘΏ Vessel on 6C 0 J GL-warms 0 In the with 2. .. '· liter of methanol ^ eraüaSöe lösiiD.g be Rühren.innerhalb' of 50 minutes at 15 0 C in portions 62 9 4 g (I '65'Mol) XiaBH entered o - Me reaction solution is stirred for 75 minutes and then, at a Badtemperatür of 60 0 C in vacuo "the residue is distributed concentrated zwisohen 1.5 liters ether and 550 ml Viasser and the aqueous phase extracted again with 500 ml of ether. The combined ether phases are filtered through charcoal and, after drying, with anhydrous Na 2 SO. concentrated under reduced pressure. This gives 178.3 g = 90.3 # d. Th.
909881/1709 ..-11-909881/1709 ..- 11-
- «* ώ - ÖAO QRIßll^AL- «* ώ - ÖAO QRIßll ^ AL
rohes l—ii—1Irxyl-J , Γ, r), (>.- - ·-·■·: rahydro-T-pyridylcarbinol 9 das ohne weiter*.· Reinigung zum Verestern eingesetzt werden kann«crude l — ii— 1 Irxyl-J, Γ, r ), (> .- - · - · ■ ·: rahydro-T-pyridylcarbinol 9 which can be used for esterification without further *. · purification «
l-Isoamyl-l,2,5 ?6-tetrahydro~3·l-Isoamyl-1,2,5? 6-tetrahydro ~ 3
18,4- g (0,1 Mol) l^TgoaEyl-ljSjSf6~t£tra*iydro~5~pyridyicarbinol und 10s2 .g (O9I Hol) absolutes Triäthylamin werden in 100 al absolutem Benzol gelöst. Unter Außenkühlung mit Eiswasser und Rühren wird innerhalb von 20 Minuten au dieser Lösung eine Lösung von 26,,5 g (O5I Mol) α,a-Diphenyl-achloracetylChlorid in 100 ml absolutem Benzol zsuge tropft. Es wird eine Stunde bei Raumtemperatur weitergerührt, von Triäthylammoniumchlorid abgesaugt und die Lösung im Yakuuin eingeengt. Der ölige Rückstand ^ird in 200 ml destilliertem Wasser gekocht, Nach der Bildung einer klaren Lösung (etwa 5 Minuten) wird mit 2 η Salzsäure ein pH-Wert von 5 - 6 eingestellt, abgekühlt und mehrmals mit kleinen Portionen Äther ausgeschüttelt. Die wäßrige Phase wirä salt Ha-bie,arbonat-Lösung alkalisch gestellt und dreimal mit je 50 ml Äther extrahiert. Hach/ffÄ TröJcniii, $ber K^Cp,. *ri5ffl dejr.lther18.4 g (0.1 mol) 1 ^ TgoaEyl-ljSjSf6 ~ t £ tra * iydro ~ 5 ~ pyridyicarbinol and 10 s 2 g (O 9 I Hol) of absolute triethylamine are dissolved in 100 μl of absolute benzene. With external cooling with ice water and stirring, a solution of 26.5 g (O 5 I mol) of α, α-diphenyl-achloroacetyl chloride in 100 ml of absolute benzene solution is added dropwise to this solution over the course of 20 minutes. Stirring is continued for an hour at room temperature, the triethylammonium chloride is filtered off with suction and the solution is concentrated in the yakuuin. The oily residue is boiled in 200 ml of distilled water. After a clear solution has formed (about 5 minutes), a pH of 5 - 6 is set with 2 η hydrochloric acid, cooled and shaken out several times with small portions of ether. The aqueous phase was made alkaline with salt carbonate solution and extracted three times with 50 ml of ether each time. Hach / ffÄ TröJcniii, $ ber K ^ Cp ,. * ri5ffl dejr.lther
und mit alkoholischer Salzsäure in das Hydrochlorid übergeführt (pH 3 - 4). Die alkohalisehe I»8sung des" Hydrochlo·^
rids wird über Kohle filtriert und mit Äther bis zur beginnenden Trübung versetzt. Ausbeute: 19 g 1-Isöamyl~l,2,5,6-"
te.trahyäro^-pyridyimethylbenEsilsäureester*- 45^d. Th.
vom Fp. 151 - 152 0C.
»hydrochlorid 9 09881/1709 - 12 -and converted into the hydrochloride with alcoholic hydrochloric acid (pH 3 - 4). The alcoholic solution of the hydrochloride is filtered through charcoal and ether is added until the onset of turbidity. Yield: 19 g of 1-isoamyl-1,2,5,6- tetrahyaro- pyridyimethylbenesilic acid ester * - 45 ^ d. Th. From mp. 151-152 0 C.
»Hydrochloride 9 09881/1709 - 12 -
l-n-Hexyl--l, 2,5 y 6-tetrahyciro-3-pyridylmethyl~benzilsäureester-methansulfonat (nach Verfahren b) 32,34 g (0,1 Mol) 1,2,S^-Tetrahydro-S-pyridylmethylbenzilsäureester und 18,2 g (0,11 Mol) 1-ri-Bromhexan werden in 75 ml absolutem Benzol in Gegenwart von 11„1 g (0,11 Mol) absolutem Triäthylamin 5 Stunden unter Rückfluß erhitzt und 15 Stunden bei Raumtemperatur belassen. Vom auskristallisierten Triäthylammoniumbromid wird abgesaugt und das Filtrat im Wasserstrahlvakuum bei maximal 500C Außentemperatur weitgehend eingeengt. Der Rückstand wird in 50 ml Alkohol gelöst, mit Methansulfonsäure auf pH 2 gestellt und mit Äther bis zur Trübung versetzt. ln-hexyl - 1,2,5 y 6-tetrahyciro-3-pyridy lmethylbenzilic acid ester methanesulfonate (according to method b) 32.34 g (0.1 mol) 1,2, S ^ -Tetrahydro-S- pyridylmethylbenzilsäureester and 18.2 g (0.11 mol) 1-ri-bromohexane are refluxed for 5 hours in 75 ml of absolute benzene in the presence of 11 "1 g (0.11 mol) of absolute triethylamine and left at room temperature for 15 hours. The triethylammonium bromide which has crystallized out is filtered off with suction and the filtrate is largely concentrated in a water jet vacuum at a maximum external temperature of 50 ° C. The residue is dissolved in 50 ml of alcohol, adjusted to pH 2 with methanesulfonic acid and mixed with ether until it becomes cloudy.
Ausbeute: 31 g = 61,5 % d. Th. vom Fp. 141 - 1420C.
Bromäthylats Fp. 177 - 1780C.
Brombutylats Fp. 144 - 145°CYield: 31 g = 61.5 % of theory . Th. Of m.p. 141-142 0 C. Bromoethylate m.p. 177-178 0 C.
Bromobutylate m.p. 144-145 ° C
1-ß-(Methoxyäthyl)-1T 2 f 5 T6-tetrahydro-3~pyrldylmethyI-benzil~ säureester-hydrochlorid (nach m yerfahren^ JpJl1 32,3 g (0,1 Mol) 1,2,5,6-Tetrahydro-3-pyridyl~methyl-benzilsäureester werden in einem Gemisch von 75 ml Tetrahydrofuran und 30 ml Dimethylformamid unter Erwärmen auf etwa 50°C gelöst und 16,8 g (0,2 Mol) wasserfreies Natriumbicarbonat zugefügt. Unter Rühren und Rückflußerhitzung werden innerhalb einer halben Stunde 15,3 g (0,11 Mol) 2-ß-(Bromäthyl)-methyläther, gelöst in 15 ml Tetrahydrofuran, und 6 ml Dimethyl- ·1-.beta. (Met hoxyäthyl) -1 T 2 f 5 T 6-tetrahydro-3 ~ pyrldylmethyI-benzil-hy ~ säureester hydrochloride (after yerfahren m ^ JpJl 1 32.3 g (0.1 mole) of 1,2, 5,6-Tetrahydro-3-pyridyl-methyl-benzilic acid esters are dissolved in a mixture of 75 ml of tetrahydrofuran and 30 ml of dimethylformamide while warming to about 50 ° C. and 16.8 g (0.2 mol) of anhydrous sodium bicarbonate are added and reflux are within half an hour 15.3 g (0.11 mol) of 2-ß- (bromoethyl) methyl ether, dissolved in 15 ml of tetrahydrofuran, and 6 ml of dimethyl ·
- 13 -909881 /1709- 13 - 909881/1709
formamid zugetropft. Nach vierstündigem Erhitzen unter Rückfluß wird von anorg^iischem Material abgesaugt und das Filtrat im siedeln Wasserbad unter Wasserstrahlvakuum weitgehend eingeengt., Der Rückstand xtrird in 30 ml Benzol gelöst, über Aktivkohle filtriert und erneut eingeengt« Die Reinigung erfolgt über Alurainumoxid (Aktivitätsstufe III) und anschließend auf einer Kieselgelsäule, jeweils mit Essigester als Laufmittel. Die Eluate werden im Wasserstrahlvakuum bei einer Badteaperatur von 500C eingeengtο Ausbeute an Base ι 2O5,15 g - 54,4 % d„ Th* Hydrochlorids Fp. 145 - 1460C.formamide was added dropwise. After four hours of refluxing, inorganic material is suctioned off and the filtrate is largely concentrated in a boiling water bath under a water jet vacuum. The residue is dissolved in 30 ml of benzene, filtered through activated charcoal and concentrated again then on a silica gel column, each with ethyl acetate as the mobile phase. The eluates are in a water jet vacuum at a Badteaperatur of 50 0 C eingeengtο yield of base ι 2O 5, 15 g - 54.4% d "Th * hydrochloride mp. 145 - 146 0 C.
l^t^i^l ^ t ^ i ^
^pJjijg^terj^h^drQcMorid ^Jjiach ¥ejg|hren a)^ Zu einer Lösung von 14„1 g (0pl Mol) l~Äthyl-l52p5p6-=tetrah¥dro-~3-PTriöylcarbinol und 10 s 2 s absolutem Triäthylamin in 100 ml wasserfreiem Benzol werden innerhalb von 30 Minuten unter Rühren und Kühlung eine Lösung von 22,3 g (0^1 Mol) ot-Cyclopeatyl-ot-phenylessigsäurechlorid in 100 ml absolutem Benzol zugetropft ο Es wird zwei Stunden bei Raumtemperatur nachgerührt s, vom ausgefallenen Triäthylammoniumchlorid abgesaugt IUId1 die bengolische Lösung im Vakuum eingeengt. Der Rückstand wird mit Wasser versetzt, mit 2 η Salzsäure schwach angesäuert und zweimal mit wenig Äther ausgeschüttelt. Die saure Lösung wird mit NaHCO, alkalisch gestellt und mit Äther extrahiert. Die mit wasserfreiem Natriumsulfat getrocknete ätherische Lösung wird im Vakuum eingeengt und die Rohbase in üblicher ^ p Jjij g ^ terj ^ h ^ drQcMorid ^ Jjiach ¥ ejg | hr en a ) ^ To a solution of 14 "1 g (0 p l mol) l ~ ethyl-l 5 2p5p6- = tetrah ¥ dro- ~ 3- PTriöylcarbinol and 10 s 2 s absolute triethylamine in 100 ml of anhydrous benzene are added dropwise within 30 minutes with stirring and cooling a solution of 22.3 g (0 ^ 1 mol) of ot-cyclopeatyl-ot-phenylacetic acid chloride in 100 ml of absolute benzene ο Es the mixture is stirred for two hours at room temperature, the precipitated triethylammonium chloride is filtered off with suction IUId 1, the bengolic solution is concentrated in vacuo. The residue is mixed with water, weakly acidified with 2 η hydrochloric acid and extracted twice with a little ether. The acidic solution is made alkaline with NaHCO 3 and extracted with ether. The ethereal solution, dried with anhydrous sodium sulfate, is concentrated in vacuo and the crude base in the usual way
90988 1/1709·. -14-90988 1/1709. -14-
Weise in das Hydrochloric! überführt. Durch Umkristallisatxon aus Acetonitril/Äther erhält man 23 g = 63,^ ^ d. Th. des analysenreinen Salzes vom Schmelzpunkt 166 - 168°C.Way into the hydrochloric! convicted. By recrystallization from acetonitrile / ether one obtains 23 g = 63, ^ ^ d. Th. Des analytically pure salt with a melting point of 166 - 168 ° C.
909881/1709909881/1709
-ULs 1929S21 - ULs 1929S21
Nach den oben beschriebenen Verfahren wurden ferner die folgenden Verbindungen erhalten:According to the method described above, the receive the following connections:
CH„ - 0CH "- 0
ItIt
R,R,
C-R-C-R-
R/R /
R/. SalzR /. salt
CH2-CH3 OH C6Hr C6H5 HClCH 2 -CH 3 OH C 6 H r C 6 H 5 HCl
Fp. 0CMp. 0 C
163163
CH2-CH3 CH 2 -CH 3
OH C6H5 Bromäthylat 190-191OH C 6 H 5 bromoethylate 190-191
CH(CH3)2 CH (CH 3 ) 2
13 (CH2)7CH3 13 (CH 2 ) 7 CH 3
14 (CH2)14 (CH 2 )
16 CH2CH=CH,16 CH 2 CH = CH,
17 CH2CH=CHCl17 CH 2 CH = CHCl
OH C6Ii5 OH C 6 Ii 5
0H C6H5 C6H5 0H C 6 H 5 C 6 H 5
OH C6H5 C6H5 OH C 6 H 5 C 6 H 5
OH C6H5 C6H5 OH C 6 H 5 C 6 H 5
OH C^HkOH C ^ Hk
OH C6H5 C6H5 OH C 6 H 5 C 6 H 5
OHOH
0 988-1 /10 988-1 / 1
Beispiel R1 R2 R3 R4 Salz Fp. 0CExample R 1 R 2 R 3 R 4 salt m.p. 0 C
18 CH2CH2C6H5 OH C6H5 C6H5 HCl . 172-17318 CH 2 CH 2 C 6 H 5 OH C 6 H 5 C 6 H 5 HCl. 172-173
19 CH2-CH3 H Cyclohexyl C6H5 HCl 203-20419 CH 2 -CH 3 H cyclohexyl C 6 H 5 HCl 203-204
20 CH2-CH3 Cyclopentan. C6H5 HCl 143-14520 CH 2 -CH 3 cyclopentane. C 6 H 5 HCl 143-145
hexylCyclo
hexyl
hexylCyclo
hexyl
909881/1709909881/1709
Pharmazeutische ÄnwendungsbeispieleExamples of pharmaceutical use
a) Dragejysa) Dragejys
1 Drageekern enthält?1 coated tablet contains?
1-n-Hexyl-l,2,5,6-tetrahydro-3-pyridylmethyl-lbeazilsäureester" -. HCl Milchzucker Maisstärke Gelatine Magnesiuiastssrat 1-n-hexyl-l, 2,5, 6-tetrahydro-3-pyridylmethyl-lbeazilsäureester. "- HCl lactose corn starch gelatin Magnesiuiastssrat
hex s teilung; ßv hex s division; ßv
Die. Hiscluing der //irksubstanz mit Illlchzucker und Ilaisütärke wird mit einer IO ','igen wäßrigen Gelatinelösung durch ein Jieb mit 3 mir; I".aschenweite granuliert, bei 40 getrocknet und nochmals durch ein Sieb gerieben. Das so erhaltene Granulat wird mit Magnesiunstearat gemischt und verpreßte .Die so erhaltenen Kerne werden in üblicher V/eise nit eir.er Hülle überzogen, die mit Hilfe eir.er v/äßrigen Suspension von Zucker·, Titandioxyd, Talkum "nd Gu.mr;.iarabicum aufgebracht wirdc Lis fertigen Dragees werden mit Bienenwachs polierte iirag'ae - Snd.gewicht; 100 n:gThe. Cluing of the irksubstoff with Illlchzucker and Ilaisut starch is carried out with an aqueous gelatin solution by a Jieb with 3 me; Granulated ash-width, dried at 40 ° and rubbed through a sieve again. The granules obtained in this way are mixed with magnesia stearate and pressed v / aqueous suspension of sugar, titanium dioxide, talc "nd Gu.mr;. arabicum is applied c Lis finished coated tablets are polished with beeswax iirag'ae - snd. weight; 100 n: g
-i!"Chyj.·=·.! j, 2, 5 · 6-=='üi-i! "Chyj. · = ·.! j, 2, 5 · 6 - == 'üi
lösliche Stärke Kagnesiiimstearatsoluble starch kagnesium stearate
HClHCl
Wirkstoff m;d !'!agnesiuBistear-at werden mit einer wäßrigen Lösung der löslichen Stärke graruliert, das Granulat getrocknet und innig mit Milchzucker und I;aisstärks vermischt. Das Gemisch wird sodann zu Tabletten von 90 mg Gewicht verpreßt, die je 3 mg 7/irkstoff enthalten«, Active ingredient m; d! '! AgnesiuBistear-at are with an aqueous Solution of the soluble starch granulated, the granules dried and intimately mixed with lactose and I; aisstarkks. The mixture is then compressed into tablets weighing 90 mg each containing 3 mg 7 / active substance «,
BAD ORIGINALBATH ORIGINAL
9 0 9 8 8' 1 / 1 7 0 S9 0 9 8 8 '1/1 7 0 p
- 19 ■ -- 19 ■ -
1 Zajichen enthält;1 zajichen contains;
1-AlIyI-I5 ?» 5,b-tetrahydro-2-1-AlIyI-I 5 ? » 5, b-tetrahydro-2-
pyrLdylm«thyl~benzi!säureester „ HCl 59O mgpyrLdylm "thyl ~ benzi! säureester" HCl 5 mg O 9
Zäpfchsnma3se 1695 90 mgSuppositories 1695 9 0 mg
170O9O mg170O 9 O mg
Herstellung -Manufacturing -
Die feinverrulverte Substanz wird mit Hilfe eines Eintauch-liomogenisators in die geschmolzene und 400C abgekühlte Zäpfchenraasse eingerührt. Die Masse wird bei 35 C in leicht vorg.ekühlte Formen gegossen»The feinverrulverte substance is stirred by means of an immersion into the molten liomogenisators and 40 0 C cooled Zäpfchenraasse. The mass is poured into slightly pre-cooled molds at 35 C »
_d l_Amjrul 1 en_d l_Amjrul 1 en
1-Ii-Hexyl·=·!,£, 55 fi=tetrahy-iro-3~pyridylnethyl-benziisä-jr.e· ester β HCl 2,0 mg1-II-Hexyl =!, £, 5 5 fi = tetrahy-iro-3-pyridylethyl-benziisä-jr.e-ester β HCl 2.0 mg
fiatriunichlorid 18,0 ι:ψ - fiatric chloride 18.0 ι: ψ -
destilliertes Wasser ad 2,0 mldistilled water to 2.0 ml
HerstellungcManufacturing c
Wirkstoff und Natritimchlorid werden in Wasser gelöst, die lösung frei von suspendie -+sn Partikeln filtriert und in 2 ccm-Ami-ullen unter &sep "isehen Bedingungen abgefüllt« Zuletzt" werden die Ampu,x~n sterilisiert und ver~ schlossen. Jede Ampulle enthalt 2 mg Wirkstoff,Natritimchlorid active ingredient and are dissolved in water, releases the solution of suspendie - + sn filtered particles and in 2 cc-Ami-Ullen under sep &"isehen conditions bottled" Last "the Ampu, closed x ~ n ~ ver and sterilized. Each ampoule contains 2 mg of active ingredient,
BAJ) 9 0 9881 /1709"'BAJ) 9 0 9881/1709 "'
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT609868A AT287711B (en) | 1968-06-25 | 1968-06-25 | Process for the preparation of new 1-alkyl-1,2,5,6-tetrahydro-3-pyridylmethyl-carboxylic acid esters and their acid addition salts and quaternary ammonium compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1929921A1 true DE1929921A1 (en) | 1970-01-02 |
Family
ID=3582843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691929921 Pending DE1929921A1 (en) | 1968-06-25 | 1969-06-12 | New 1-alyl-1,2,5,6-tetrahydro-3-pyridylmethyl-carboxylic acid esters and their acid addition salts and quaternary ammonium compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3627775A (en) |
| AT (1) | AT287711B (en) |
| BE (1) | BE735141A (en) |
| BR (1) | BR6910094D0 (en) |
| CH (1) | CH513164A (en) |
| DE (1) | DE1929921A1 (en) |
| ES (3) | ES368698A1 (en) |
| FR (1) | FR2014218A1 (en) |
| GB (1) | GB1257960A (en) |
| IL (1) | IL32469A0 (en) |
| NL (1) | NL6909425A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0325263A1 (en) * | 1988-01-21 | 1989-07-26 | Boehringer Ingelheim Kg | Tetrahydropyridine derivatives |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4467095A (en) * | 1969-02-10 | 1984-08-21 | Fmc Corporation | Anticholinergic compounds |
| US3879556A (en) * | 1970-09-02 | 1975-04-22 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing a 1,2,3,6-tetrahydro-4-pyridylmethyl carboxylate and method of use |
| DE2043455A1 (en) * | 1970-09-02 | 1972-03-09 | CH. Boehringer Sohn, 6507 Ingelheim | New l, 2,3,6-tetrahydro-4-pyridylmethyl-carboxylic acid esters, as well as their acid addition salts and quaternary ammonium compounds |
| FR2501682A1 (en) * | 1981-03-11 | 1982-09-17 | Sanofi Sa | TRIPLUOROMETHYLPHENYLPYRIDINES WITH ANOREXIGENE ACTIVITY, A PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2607777A (en) * | 1947-04-10 | 1952-08-19 | Searle & Co | N-alkyl piperidyl alkyl esters of diphenyl acetic acid and 9-fluorenyl carboxylic acid |
| GB886437A (en) * | 1959-07-15 | 1962-01-10 | Beecham Res Lab | Improvements in or relating to basic esters of etherified benzilic acids |
-
1968
- 1968-06-25 AT AT609868A patent/AT287711B/en not_active IP Right Cessation
-
1969
- 1969-06-12 DE DE19691929921 patent/DE1929921A1/en active Pending
- 1969-06-19 NL NL6909425A patent/NL6909425A/xx unknown
- 1969-06-23 CH CH958769A patent/CH513164A/en not_active IP Right Cessation
- 1969-06-23 ES ES368698A patent/ES368698A1/en not_active Expired
- 1969-06-24 IL IL32469A patent/IL32469A0/en unknown
- 1969-06-24 BR BR210094/69A patent/BR6910094D0/en unknown
- 1969-06-25 FR FR6921376A patent/FR2014218A1/fr not_active Withdrawn
- 1969-06-25 US US836658A patent/US3627775A/en not_active Expired - Lifetime
- 1969-06-25 GB GB1257960D patent/GB1257960A/en not_active Expired
- 1969-06-25 BE BE735141D patent/BE735141A/xx unknown
- 1969-12-10 ES ES374408A patent/ES374408A1/en not_active Expired
- 1969-12-10 ES ES374407A patent/ES374407A1/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0325263A1 (en) * | 1988-01-21 | 1989-07-26 | Boehringer Ingelheim Kg | Tetrahydropyridine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| IL32469A0 (en) | 1969-08-27 |
| ES368698A1 (en) | 1971-07-01 |
| BE735141A (en) | 1969-12-29 |
| GB1257960A (en) | 1971-12-22 |
| FR2014218A1 (en) | 1970-04-17 |
| ES374408A1 (en) | 1972-01-01 |
| BR6910094D0 (en) | 1973-04-05 |
| ES374407A1 (en) | 1972-01-01 |
| US3627775A (en) | 1971-12-14 |
| CH513164A (en) | 1971-09-30 |
| NL6909425A (en) | 1969-12-30 |
| AT287711B (en) | 1971-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1543715A1 (en) | Process for the preparation of basic derivatives of phthalans and isochromans | |
| DE1643262C3 (en) | i-Phenoxy ^ -hydroxy-S-alklyaminopropane, process for their preparation and medicaments containing these compounds | |
| DD263980A5 (en) | METHOD OF PREPARING NEW DIPHENYL-PROPYLAMINE DERIVATIVES | |
| EP0043940B1 (en) | 3,1-benzoxazin-2-ones, their preparation and their use | |
| DE3420193A1 (en) | NEW SUBSTITUTED PYRROLIDINONES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS | |
| DE2718405A1 (en) | NEW N-NECK CLAMP ON 1- (3-BENZOYLPROPYL) -4-PIPERIDYL NECK CLAMP ON -SULPHONIC ACID AMIDES AND METHOD FOR THE PRODUCTION THEREOF | |
| DE3211934A1 (en) | SALICYL ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE | |
| DD145104B3 (en) | PROCESS FOR PREPARING POLYALKOXYPHENYLPYRROLIDONE | |
| DE3326724A1 (en) | 4-HYDROXYMETHYL-PYRROLIDINONE SUBSTITUTED IN 1 POSITION, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE PRODUCTS | |
| DE3049959C2 (en) | ||
| DE1929921A1 (en) | New 1-alyl-1,2,5,6-tetrahydro-3-pyridylmethyl-carboxylic acid esters and their acid addition salts and quaternary ammonium compounds | |
| CH618439A5 (en) | ||
| DE3315797A1 (en) | SUBSTITUTED PHENYL-2- (1H) -PYRIMIDINONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE, AND PREPARATIONS CONTAINING THESE COMPOUNDS | |
| CH642966A5 (en) | 1-(2-Chlorophenyl)-4-[2-(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzox epin-1-yl)ethyl]piperazine and pharmacologically acceptable acid addition salts thereof | |
| DE2351281C3 (en) | Aminophenylethanolamine derivatives, their production and use | |
| DE2427272C3 (en) | 1- (2- (β-Naphthyloxy) ethyl) -3-methyl-pyrazolone- (5), method and use as an antithrombotic | |
| DE2831671A1 (en) | NEW SUBSTITUTED 2-PHENYLAMINO-IMIDAZOLINE (2), THE ACID ADDITION SALTS THEREOF, THE MEDICINAL PRODUCTS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF | |
| AT319936B (en) | Process for the preparation of new phenylimidazolidinone derivatives and their salts | |
| DD150060A5 (en) | PROCESS FOR THE PREPARATION OF NEW PHENTHIAZINE DERIVATIVES | |
| DE2309887C2 (en) | 1-aryloxy-2-hydroxy-3-alkynylaminopropane derivatives and their physiologically acceptable acid addition salts, pharmaceutical preparations and manufacturing processes for the compounds | |
| DE2043455A1 (en) | New l, 2,3,6-tetrahydro-4-pyridylmethyl-carboxylic acid esters, as well as their acid addition salts and quaternary ammonium compounds | |
| DE69500156T2 (en) | Imidazopyridine derivatives and process for their preparation | |
| AT287718B (en) | Process for the preparation of new 1-alkyl-1,2,5,6-tetrahydro-3-pyridylmethyl-carboxylic acid esters and their acid addition salts and quaternary ammonium compounds | |
| DE2114893A1 (en) | New basic substituted thiol carbamic acid alkyl esters and processes for their preparation | |
| DE1543928C (en) | Amino dihalogen phenyl ethanolamine, process for their preparation and pharmaceuticals containing them |